Company Overview of Bayer HealthCare AG
Bayer HealthCare AG discovers, develops, manufactures, and markets products that help to prevent, diagnose, and treat diseases for humans and animals worldwide. The company operates through four divisions: Animal Health, Consumer Care, Medical Care, and Pharmaceuticals. The Animal Health division produces and distributes various animal health and care products, which include flea and tick-control solutions, anti-infective products, and endoparasitics for farm and companion animals. The Consumer Care division offers over-the-counter products, such as analgesics, gastrointestinal products, dermatological/topical products, cough and cold remedies, and multivitamins and dietary supplements. It s...
Building Q 30
Founded in 1863
Key Executives for Bayer HealthCare AG
Chairman of Management Board
Chief Financial Officer and Head of Central Administration & Organization
Head of Product Supply and Member of Management Board
Chief Operating Officer of Bayer CropScience and Member of Executive Committee
Head of Global Drug Discovery
Compensation as of Fiscal Year 2015.
Bayer HealthCare AG Key Developments
Bayer HealthCare and Union Settle Four Year Contract
Aug 4 15
Bayer HealthCare and the union representing some 450 workers in Berkeley agreed on a four-year contract that includes annual pay increases of at least 3.2%. The new contract, settled a month before the current four-year pact expires on Aug. 25, was ratified by members of the International Longshore and Warehouse Union Local 6. The new deal ends Aug. 24, 2019. Production and supply workers at the Berkeley facility - the only unionized biotech manufacturing workforce in the United States - currently make about $67,000 a year, according to a report last year from Bayer to Berkeley city offiicials. Bayer this spring broke ground on a $100 million testing facility in Berkeley, where it currently makes and tests Bayer's second-best-selling product, the blood-clotting drug Kogenate FS for hemophilia A patients. But Bayer, for the first time, plans to make two products in Berkeley, if the Food and Drug Administration later this year approves a hemophilia A treatment called Kovaltry.
Bayer HealthCare and Sprint Bioscience AB Collaborate to Develop Oncological Drug Candidates
Aug 3 15
Bayer HealthCare and Sprint Bioscience AB have entered into a collaboration and license agreement for the research, development, and commercialization of new oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer. Subsequently, Bayer will have full control over further development and worldwide commercialization rights for potential cancer therapeutics and diagnostics.
Bayer Healthcare Wins US FDA Approval for Finacea for Treating Inflammatory Papules and Pustules of Mild to Moderate Rosacea
Aug 3 15
Bayer HealthCare reported that it has received the US Food & Drug Administration's (FDA) approval for Finacea (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. According to the company, Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. The company added that Finacea Foam was developed as part of a research and development collaboration with Foamix Pharmaceuticals utilising Foamix's proprietary foam technology platform. Under the license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialisation of Finacea Foam. Beginning September 2015, Finacea Foam will be marketed in the US by Bayer HealthCare and will be available by prescription.
Similar Private Companies By Industry
Recent Private Companies Transactions